← All diseases

Lysosomal storage diseases

Lysosomal acid lipase deficiency (LAL-D)

An inherited disease that causes fat and cholesterol to build up in the cells. It mainly affects the liver. It can begin in infancy or later.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

This page is translated from the Turkish original.

This disease is followed through the “Lysosomal storage diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

An enzyme called lysosomal acid lipase is missing in the cells. This enzyme breaks down fats and cholesterol. When it is missing, fats build up in the cells, mostly in the liver. The liver grows larger and can harden over time.

Which symptoms can occur?

The disease has two forms. The severe form begins in infancy, in the first weeks, and is the rarest. The milder form begins in childhood or adulthood.

  • Enlarged liver (in almost all with the later form)
  • Enlarged spleen (common)
  • Vomiting, diarrhea and fatty stools
  • Poor weight gain (in infancy)
  • Yellowing of the skin and eyes (in infancy)
  • High cholesterol and liver values in the blood
  • Hardening of the liver, called cirrhosis (sometimes)

How is it diagnosed?

Blood tests may show high liver values and cholesterol. Enzyme activity is measured in the blood; a dried blood spot can also be used. The diagnosis is confirmed with a genetic test that looks at the LIPA gene.

Treatment and care

There is an approved enzyme treatment specific to the disease. In the infant form, early diagnosis and treatment are very important. Babies are also given a special fat-restricted diet and vitamin supplements. A stem cell or liver transplant may be considered for some people. Cholesterol and the liver are checked regularly. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Diseases of this kind may be more common in marriages between relatives. Testing brothers and sisters is important for early treatment. Genetic counselling is recommended.

Source: MedlinePlus Genetics: Lysosomal acid lipase deficiency · GeneReviews: Lysosomal Acid Lipase Deficiency

Key facts

How common is it?
Prevalence: 1-9 per 100 000 (Europe)
How is it inherited?
Autosomal recessive
When does it usually start?
Adolescence, Adulthood, Childhood, Infancy, Newborn period

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

For all rare diseases: Nadir Hastalıklar Federasyonu

Links checked on October 8, 2026.

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about LAL deficiency

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 1 active interventional study for this disease. 1 is recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Lysosomal storage diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:275761

No separate ICD-11 code; WHO classifies this disease under: 5C56.0Y

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.